This review investigated the clinical effectiveness and cost-effectiveness of insulin treatment for diabetes, by comparing continuous subcutaneous insulin infusion (from a pump) with multiple daily injections. It concluded that continuous infusion treatment resulted in a modest improvement in glycated haemoglobin levels in adults with type 1 diabetes. This was a well-conducted review and most of the conclusions are justified.
Assessment of study quality
The quality of the RCTs and crossover studies was assessed using checklists reported by the Centre for Reviews and Dissemination (see Other Publications of Related Interest no.1 The quality criteria were applied by one reviewer and checked by a second. Any discrepancies were resolved through discussion or in consultation with a third reviewer.
Data extraction
One reviewer extracted the data and a second reviewer checked the extraction. Any discrepancies were resolved through discussion or in consultation with a third reviewer. Data on study design, treatments, the numbers of patients, baseline patient characteristics, study methodology and outcomes were extracted. The mean changes from baseline in glycated haemoglobin and the mean daily insulin dose for each treatment group, along with the difference between them, were extracted. Data on patient preference, adverse events and weight change for each treatment group were also extracted.
Methods of synthesis
How were the studies combined?
The data were combined in a narrative. Where appropriate, the weighted mean difference (WMD) between CSII and MDI for glycated haemoglobin and insulin dose were combined using a random-effects model.
How were differences between studies investigated?
Details of the study settings, interventions, patients, outcomes and methods were presented in tabular format, according to the patient group assessed. Differences between the study results for glycated haemoglobin and daily insulin dose were investigated statistically using a chi-squared test.
A sensitivity analysis was also performed by excluding non-randomised crossover studies from the meta-analysis.
Results of the review
Twenty studies (n=646) comparing CSII with MDI were included. Fourteen studies assessed adults with type 1 diabetes: 4 RCTs (n=197), 7 randomised crossover studies (n=128) and 3 non-randomised crossover studies (n=119). Four RCTs assessed pregnant women (n=172) and 2 randomised crossover studies assessed adolescents (n=30).
The quality of the reporting and methodology of the included studies was generally poor.
Adults with type 1 diabetes.
After up to 4 months' treatment (5 studies), CSII was associated with an overall reduction in glycated haemoglobin of 0.64% in comparison with MDI (WMD -0.64, 95% confidence interval, CI: -1.28, 0.01); this reduction was 0.26% (WMD -0.26, 95% CI: -0.57, 0.05) after 6 months (3 studies), and 0.61% (WMD -0.61, 95% CI: -1.29, 0.07) after 12 months (2 studies). Statistically significant heterogeneity was found for the 4-month results (P=0.0035), but not at 6 or 12 months. CSII treatment also led to an overall reduction in the daily insulin dose of 12 units per day (WMD -11.9, 95% CI: -18.16, -5.63) after 4 months, although there was statistically significant heterogeneity between the individual study results (P=0.0002). The results of the sensitivity analyses, which excluded non-randomised studies, were similar. Body weight remained similar in both groups during treatment. Four of the 8 studies with results for patient preference reported that more patients preferred CSII treatment.
Pregnant women.
There was insufficient evidence from the 4 studies in pregnant women that glycated haemoglobin levels or insulin dose differed between CSII and MDI treatment.
Adolescents.
One study found a statistically significant reduction in both glycated haemoglobin (8.8% versus 9.6%, P<0.05) and the total daily insulin dose (44 versus 60 units per day, P<0.001) after 4 months of CSII treatment, compared with MDI.
